Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors - PubMed (original) (raw)
Observational Study
doi: 10.1159/000360011. Epub 2014 Feb 21.
Affiliations
- PMID: 24577494
- DOI: 10.1159/000360011
Free article
Observational Study
Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors
Mohamad Alhosaini et al. Am J Nephrol. 2014.
Free article
Abstract
Background: Recent observations have associated hypomagnesemia with increased risk of cardiovascular morbidity and mortality in hemodialysis patients.
Methods: We did a 3-month chart review of 62 chronic hemodialysis patients at a single US hospital. All were dialyzed using a dialysate [Mg] of 0.75-1.0 mEq/l. Patients were divided into two groups: hypomagnesemic (mean predialysis plasma [Mg] <1.5 mEq/l) and non-hypomagnesemic (mean predialysis plasma [Mg] ≥1.5 mEq/l).
Results: All patients were male; mean age was 64.3 ± 8.7 years and the majority (73%) diabetic. 24 patients (39%) had hypomagnesemia and 38 (61%) were not hypomagnesemic. There were no significant differences between the two groups in age, diabetes status, blood pressure, duration of dialysis, plasma calcium, phosphorus, albumin, intact parathyroid hormone (PTH), dialysis adequacy (Kt/V), or dietary protein intake (as estimated by normalized protein catabolic rate, nPCR). However, use of proton pump inhibitors (PPIs) was significantly associated with hypomagnesemia (plasma [Mg] 1.48 ± 0.16 mEq/l in the PPI group vs. 1.65 ± 0.26 mEq/l in the non-PPI group, p = 0.007). Adjustment for age, diabetes status, duration of dialysis, plasma albumin, Kt/V, nPCR, and diuretic use did not affect the association between PPI use and hypomagnesemia.
Conclusions: Use of PPIs in patients dialyzed using a dialysate [Mg] of 0.75-1.0 mEq/l is associated with hypomagnesemia. We suggest monitoring plasma [Mg] in patients taking PPIs, with discontinuation of the medication if possible and/or adjustment of dialysate [Mg] to normalize plasma [Mg].
Similar articles
- Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.
Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M, Franco OH, Kuipers EJ, Hofman A, Zietse R, Stricker BH, Hoorn EJ. Kieboom BC, et al. Am J Kidney Dis. 2015 Nov;66(5):775-82. doi: 10.1053/j.ajkd.2015.05.012. Epub 2015 Jun 26. Am J Kidney Dis. 2015. PMID: 26123862 - The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study.
Misra PS, Alam A, Lipman ML, Nessim SJ. Misra PS, et al. BMC Nephrol. 2015 Aug 13;16:136. doi: 10.1186/s12882-015-0139-9. BMC Nephrol. 2015. PMID: 26268579 Free PMC article. - Serum Magnesium and Mortality in Hemodialysis Patients in the United States: A Cohort Study.
Lacson E Jr, Wang W, Ma L, Passlick-Deetjen J. Lacson E Jr, et al. Am J Kidney Dis. 2015 Dec;66(6):1056-66. doi: 10.1053/j.ajkd.2015.06.014. Epub 2015 Jul 17. Am J Kidney Dis. 2015. PMID: 26190226 - Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us?
Luk CP, Parsons R, Lee YP, Hughes JD. Luk CP, et al. Ann Pharmacother. 2013 Jun;47(6):773-80. doi: 10.1345/aph.1R556. Epub 2013 Apr 30. Ann Pharmacother. 2013. PMID: 23632281 Review. - Hypomagnesemia and proton-pump inhibitors.
Famularo G, Gasbarrone L, Minisola G. Famularo G, et al. Expert Opin Drug Saf. 2013 Sep;12(5):709-16. doi: 10.1517/14740338.2013.809062. Epub 2013 Jun 29. Expert Opin Drug Saf. 2013. PMID: 23808631 Review.
Cited by
- Association between magnesium, erythropoietin resistance and mortality: the Japanese Dialysis Outcomes and Practice Patterns Study (J-DOPPS).
Kato S, Wang J, Onishi Y, Nangaku M. Kato S, et al. Clin Kidney J. 2024 Jun 21;17(7):sfae153. doi: 10.1093/ckj/sfae153. eCollection 2024 Jul. Clin Kidney J. 2024. PMID: 38966575 Free PMC article. - Lower product of magnesium × potassium is associated with higher mortality in chronic hemodialysis patients: a cohort study.
Chen JY, Jiang MY, Huang YT, Hwang JC. Chen JY, et al. Sci Rep. 2023 Dec 13;13(1):22128. doi: 10.1038/s41598-023-49372-y. Sci Rep. 2023. PMID: 38092856 Free PMC article. - Effects of Proton Pump Inhibitors on Patient Survival in Patients Undergoing Maintenance Hemodialysis.
Kang SH, Kim GO, Kim BY, Son EJ, Do JY. Kang SH, et al. J Clin Med. 2023 Jul 18;12(14):4749. doi: 10.3390/jcm12144749. J Clin Med. 2023. PMID: 37510864 Free PMC article. - Choosing the right chronic medication for hemodialysis patients. A short ABC for the dialysis nephrologist.
Roux C, Verollet K, Prouvot J, Prelipcean C, Pambrun E, Moranne O. Roux C, et al. J Nephrol. 2023 Mar;36(2):521-536. doi: 10.1007/s40620-022-01477-9. Epub 2022 Dec 6. J Nephrol. 2023. PMID: 36472789 Review. - Incidence, Pathogenesis, and Management of Proton Pump Inhibitor-Induced Nephrotoxicity.
Wei X, Yu J, Xu Z, Wang C, Wu Y. Wei X, et al. Drug Saf. 2022 Jul;45(7):703-712. doi: 10.1007/s40264-022-01181-4. Epub 2022 Jun 1. Drug Saf. 2022. PMID: 35641849 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical